Press Releases<< Back
CHF Solutions, Inc. Announces 14 Percent Increase in Revenue for Second Quarter 2020 Over Previous Quarter and Provides Company Update
- Revenue for the second quarter ended
June 30, 2020, was $1.9 million, an increase of 14 percent from the first quarter of 2020 and 11 percent compared to the same period of the prior year.
- Hosted two physician-led webinars on treatment of critically ill, COVID-19 patients, including a discussion of the publication SARS-CoV-2 (COVID-19) and intravascular volume management strategies in the critically ill.1 which addressed the role of ultrafiltration in the treatment of COVID-19 patients.
- Hosted a webinar led by Dr.
David Askenazi, M.D. MSPH on treatment of fluid overload on pediatric patients. Announced partnership for a pediatric registry.
- Announced the signing of a new a distribution arrangement to sell in the
United Arab Emirates, effectively initiating presence in the Middle East.
- Submitted a patent application for an adaptation of Aquadex SmartFlow™ system to rapidly clear cytokines.
- Initiated a distribution agreement with
Renal Sense, Ltd.to market and sell complementary real-time monitoring of patient’s renal function to prevent acute kidney injury.
- Ended the quarter with
$7.8 millionin cash and no debt. During the quarter, closed on two registered direct offering for next proceeds of $3.4 million, and received $2.1 millionfrom warrant exercises.
“We continue to be very pleased that we produce a product that is providing a meaningful therapy for treating the COVID-19 patients,” said
The Company will host a conference call and webcast at
About the Aquadex SmartFlow System
The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.
Certain statements in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the value that the company brings to its customers. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our ability to execute on our commercialization strategy, the impact of the COVID-19 pandemic, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made.
Condensed Consolidated Statements of Operations and Comprehensive Loss
(unaudited, in thousands, except per share amounts)
||Three months ended
||Six months ended
|Costs and expenses:|
|Cost of goods sold||664||835||1,460||1,447|
|Selling, general and administrative||4,234||3,973||8,770||7,991|
|Research and development||885||1,297||1,749||2,607|
|Total costs and expenses||5,783||6,105||11,979||12,045|
|Loss from operations||(3,920||)||(4,428||)||(8,486||)||(9,153||)|
|Loss before income taxes||(3,920||)||(4,428||)||(8,486||)||(9,153||)|
|Income tax expense||(2||)||(2||)||(4||)||(4||)|
|Basic and diluted loss per share||$||(0.10||)||$||(1.93||)||$||(0.37||)||$||(8.82||)|
|Weighted average shares outstanding – basic and diluted||37,923||2,295||27,181||1,550|
|Other comprehensive loss:|
|Foreign currency translation adjustments||$||(2||)||$||(3||)||$||(5||)||$||(5||)|
|Total comprehensive loss||$||(3,924||)||$||(4,433||)||$||(8,495||)||$||(9,162||)|
Condensed Consolidated Balance Sheets
(in thousands, except share and per share amounts)
|Cash and cash equivalents||$||7,821||$||1,279|
|Other current assets||141||161|
|Total current assets||11,729||4,036|
|Property, plant and equipment, net||1,042||991|
|Operating lease right-of-use asset||351||442|
|LIABILITIES AND STOCKHOLDERS’ EQUITY|
|Current portion of operating lease liability||196||186|
|Current portion of finance lease liability||17||—|
|Other current liabilities||40||85|
|Total current liabilities||3,335||3,351|
|Operating lease liability||160||261|
|Finance lease liability||46||—|
|Commitments and contingencies|
|Series A junior participating preferred stock as of
|Series F convertible preferred stock as of
|Preferred stock as of
|Common stock as of
43,196,813 and 4,674,068, respectively
|Additional paid‑in capital||234,381||218,278|
|Accumulated other comprehensive income:|
|Foreign currency translation adjustment||1,209||1,214|
|Total stockholders’ equity||9,602||1,990|
|TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY||$||13,143||$||5,602|
Condensed Consolidated Statements of Cash Flows
(unaudited, in thousands)
|Six months ended
|Adjustments to reconcile net loss to cash flows used in operating activities:|
|Depreciation and amortization||151||120|
|Stock-based compensation expense, net||727||701|
|Loss on disposal of property and equipment||46||—|
|Changes in operating assets and liabilities:|
|Other current assets||20||(75||)|
|Other assets and liabilities||112||(18||)|
|Accounts payable and accrued expenses||(43||)||(267||)|
|Net cash used in operating activities||(8,760||)||(8,874||)|
|Purchases of property and equipment||(69||)||(158||)|
|Net cash used in investing activities||(69||)||(158||)|
|Proceeds from public stock offerings, net||13,040||10,959|
|Proceeds from warrant exercises||2,340||—|
|Payments on finance lease liability||(4||)||—|
|Net cash provided by financing activities||15,376||10,959|
|Effect of exchange rate changes on cash||(5||)||(5||)|
|Net increase in cash and cash equivalents||6,542||1,922|
|Cash and cash equivalents - beginning of period||1,279||5,480|
|Cash and cash equivalents - end of period||$||7,821||$||7,402|
|Supplemental cash flow information|
|Cash paid for income taxes||$||—||$||—|
|Inventory transferred to property, plant and equipment||$||112||$||—|
|Equipment acquired through finance lease liability||$||67||$||—|
Claudia Napal DraytonChief Financial Officer CHF Solutions, Inc.952-345-4205 firstname.lastname@example.org MEDIA: Jessica StebingHealth+Commerce 260-336-6202 email@example.com
Source: CHF Solutions, Inc.